肾移植预后生物标志物:系统综述与批判性评估
该研究系统检索2005至2022年文献,纳入804项肾移植预后生物标志物研究,发现多数为单中心回顾性设计、样本量小、外部验证不足5%,且报告透明度和可重复性差,提示该领域研究质量亟待提高。
要点
- 肾移植生物标志物研究数量增长快,但临床转化少,设计与报告质量普遍欠佳。
- 仅4.7%的研究进行外部验证,43.0%未调整关键预后因素,仅3.1%调整常规监测因素。
- 数据共享、代码共享和注册率分别仅8.8%、1.1%和4.6%,透明度不足。
核心结论
- 肾移植生物标志物研究缺乏验证、严谨设计、准确解读和透明度,需更高标准以证明临床效用。
研究设计与样本
- 系统综述与批判性评估,检索PubMed、Embase、Scopus、Web of Science和Cochrane Library(2005年1月1日至2022年11月12日),纳入804项英文原创研究。
主要发现
- 共评估1143种生物标志物,来自血液(821种,71.8%)、移植物内(169种,14.8%)和尿液(81种,7.1%)。
- 655项研究(81.5%)为回顾性,595项(74.0%)为单中心,患者中位数232例(IQR 96-629),随访中位数4.8年(IQR 3.0-6.2)。
- 仅4.7%的研究进行外部验证,43.0%未调整关键预后因素,3.1%调整了常规监测因素。
- 数据共享、代码共享和注册率分别为8.8%、1.1%和4.6%。
- 158项研究(20.0%)在报告生物标志物与结局无显著关联时仍强调其临床相关性。
临床怎么用
- 临床医生应审慎看待肾移植生物标志物研究结论,优先关注经过外部验证且调整了常规监测因素的研究。
局限性
- 仅纳入英文原创研究,未涉及非英文文献;研究异质性未做定量合并。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Why are there so few biomarkers accepted by health authorities and implemented in clinical practice, despite the high and growing number of biomaker studies in medical research ? In this meta-epidemiological study, including 804 studies that were critically appraised by expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency. The authors also demonstrated for the first time that the limited number of studies challenged the added value of their candidate biomarkers against standard-of-care routine patient monitoring parameters. Most biomarker studies tended to be single-center, retrospective studies with a small number of patients and clinical events. Less than 5% of the studies performed an external validation. The authors also showed the poor transparency reporting and identified a data beautification phenomenon. These findings suggest that there is much wasted research effort in transplant biomarker medical research and highlight the need to produce more rigorous studies so that more biomarkers may be validated and successfully implemented in clinical practice. BACKGROUND: Despite the increasing number of biomarker studies published in the transplant literature over the past 20 years, demonstrations of their clinical benefit and their implementation in routine clinical practice are lacking. We hypothesized that suboptimal design, data, methodology, and reporting might contribute to this phenomenon. METHODS: We formed a consortium of experts in systematic reviews, nephrologists, methodologists, and epidemiologists. A systematic literature search was performed in PubMed, Embase, Scopus, Web of Science, and Cochrane Library between January 1, 2005, and November 12, 2022 (PROSPERO ID: CRD42020154747). All English language, original studies investigating the association between a biomarker and kidney allograft outcome were included. The final set of publications was assessed by expert reviewers. After data collection, two independent reviewers randomly evaluated the inconsistencies for 30% of the references for each reviewer. If more than 5% of inconsistencies were observed for one given reviewer, a re-evaluation was conducted for all the references of the reviewer. The biomarkers were categorized according to their type and the biological milieu from which they were measured. The study characteristics related to the design, methods, results, and their interpretation were assessed, as well as reproducible research practices and transparency indicators. RESULTS: A total of 7372 publications were screened and 804 studies met the inclusion criteria. A total of 1143 biomarkers were assessed among the included studies from blood ( n =821, 71.8%), intragraft ( n =169, 14.8%), or urine ( n =81, 7.1%) compartments. The number of studies significantly increased, with a median, yearly number of 31.5 studies (interquartile range [IQR], 23.8-35.5) between 2005 and 2012 and 57.5 (IQR, 53.3-59.8) between 2013 and 2022 ( P < 0.001). A total of 655 studies (81.5%) were retrospective, while 595 (74.0%) used data from a single center. The median number of patients included was 232 (IQR, 96-629) with a median follow-up post-transplant of 4.8 years (IQR, 3.0-6.2). Only 4.7% of studies were externally validated. A total of 346 studies (43.0%) did not adjust their biomarker for key prognostic factors, while only 3.1% of studies adjusted the biomarker for standard-of-care patient monitoring factors. Data sharing, code sharing, and registration occurred in 8.8%, 1.1%, and 4.6% of studies, respectively. A total of 158 studies (20.0%) emphasized the clinical relevance of the biomarker, despite the reported nonsignificant association of the biomarker with the outcome measure. A total of 288 studies assessed rejection as an outcome. We showed that these rejection studies shared the same characteristics as other studies. CONCLUSIONS: Biomarker studies in kidney transplantation lack validation, rigorous design and methodology, accurate interpretation, and transparency. Higher standards are needed in biomarker research to prove the clinical utility and support clinical use.
引用
- Raynaud M, Al-Awadhi S, Louis K, et al. Prognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal. J Am Soc Nephrol. 2023. PMID: 38053242. doi:10.1681/ASN.0000000000000260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。